Exelixis Inc Proceeds from Issuance of Debt
Exelixis Inc (EXEL) reported Proceeds from Issuance of Debt of $0 for the 12-month period ending 2014-12-31, per its 10-K filed 2015-03-02.
Discontinued › Cash Flow › Financing Activities
us-gaap:ProceedsFromIssuanceOfDebt · last filed 2015-03-02
- Exelixis Inc proceeds from issuance of debt for the quarter ending 2013-12-31 was $0.00.
- Exelixis Inc proceeds from issuance of debt for the quarter ending 2012-12-31 was $0.00.
- Exelixis Inc proceeds from issuance of debt for the quarter ending 2012-09-30 was $277.67M.
- Exelixis Inc proceeds from issuance of debt for the quarter ending 2011-12-31 was $0.00.
- Exelixis Inc proceeds from issuance of debt for fiscal 2014 was $0.00.
- Exelixis Inc proceeds from issuance of debt for fiscal 2013 was $0.00, a 100.00% decline from fiscal 2012.
- Exelixis Inc proceeds from issuance of debt for fiscal 2012 was $277.67M, a 10625.11% increase from fiscal 2011.
- Exelixis Inc proceeds from issuance of debt for fiscal 2011 was $2.59M, a 98.43% decline from fiscal 2010.
| Period end | Proceeds from Issuance of Debt 3 month | Proceeds from Issuance of Debt 6 month | Proceeds from Issuance of Debt 9 month | Proceeds from Issuance of Debt 9 month as first filed | Proceeds from Issuance of Debt 12 month |
|---|---|---|---|---|---|
| 2014-12-31 | $0.00 10-K · filed 2015-03-02 | ||||
| 2013-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-02 | $0.00 10-K · filed 2015-03-02 | |||
| 2013-09-30 | $0.00 10-Q · filed 2013-10-30 | ||||
| 2012-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-02 | $277.67M derived: sum of 2 quarters · filed 2015-03-02 | $277.67M 10-K · filed 2015-03-02 | ||
| 2012-09-30 | $277.67M derived: 10-Q 9 month − 10-Q 6 month · filed 2013-10-30 | $277.67M 10-Q · filed 2013-10-30 | $0.00 10-Q · filed 2012-11-07 | ||
| 2012-06-30 | $0.00 10-Q · filed 2012-08-02 | ||||
| 2011-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2014-02-20 | $0.00 derived: sum of 2 quarters · filed 2014-02-20 | $2.59M 10-K · filed 2014-02-20 | ||
| 2011-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2012-11-07 | $2.59M 10-Q · filed 2012-11-07 | |||
| 2011-06-30 | $2.59M 10-Q · filed 2012-08-02 | ||||
| 2010-12-31 | $165.01M 10-K · filed 2013-02-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |